Related Experiment Video
Updated: Apr 27, 2026
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Studying cancer treatment in the elderly patient population
1Senior Adult Oncology Program, Moffitt Cancer Center, Tampa, FL 33612, USA. Lodovico.Balducci@Moffitt.org.
Background:
Data relating to cancer treatment in the older patient population are limited because older individuals have been under-represented in clinical trials. The goal of this review was to establish which factors hinder the participation of older individuals to clinical trials and to examine possible solutions.
Methods:
The literature relating to cancer treatment in the older patient population was reviewed.
Results:
The benefit of systemic cancer treatment may decrease with age, and risks may be increased due to reduced life expectancy and reduced tolerance of stress in the older population. Therefore, a multipronged approach is recommended for clinical studies in these patients, including phase 2 studies limited to persons 70 years of age and older, stratification by life expectancy and predicted treatment tolerance in phase 3 studies, and registration studies to establish predictive variables for treatment-related toxicity in older individuals.
Conclusions:
A combination of prospective and registration studies may supply adequate information to study cancer treatments in the older patient population.
Insights
Older adults are under-represented in cancer clinical trials. This review suggests specific study designs to improve enrollment and gather vital data on cancer treatments for the elderly.
Area of Science:
- Geriatric Oncology
- Clinical Trial Design
- Cancer Research
Background:
- Limited data exists on cancer treatment efficacy and safety in older adults due to their under-representation in clinical trials.
- Older patients face unique challenges and physiological changes that impact treatment tolerance and outcomes.
- Understanding barriers to participation is crucial for improving research inclusivity.
Purpose of the Study:
- To identify factors hindering the participation of older individuals in cancer clinical trials.
- To propose solutions and optimized study designs for this demographic.
- To enhance the evidence base for geriatric cancer treatment.
Main Methods:
- A comprehensive literature review was conducted on cancer treatment studies involving the older patient population.
- Analysis focused on identifying barriers to participation and evaluating existing research methodologies.
- Synthesized findings to recommend improved clinical trial approaches.
Main Results:
- Cancer treatment benefits may diminish with age, while risks, including reduced life expectancy and stress tolerance, can increase.
- A multipronged approach is recommended for clinical studies in older patients.
- This includes age-specific phase 2 studies, stratification by life expectancy and tolerance in phase 3 studies, and registration studies for toxicity prediction.
Conclusions:
- A combination of prospective and registration studies is proposed to adequately gather information on cancer treatments for older adults.
- Optimized study designs are essential for generating reliable data in geriatric oncology.
- Improved research strategies will lead to better cancer care for the aging population.
Related Concept Videos
01:15Drug Dosing: Geriatric Patients
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
01:21Cancer Survival Analysis